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Abstract Since 1990, the primary criteria used for assessing
response to therapy in high-grade gliomas were those devel-
oped by Macdonald and colleagues, which incorporated 2-
dimensional area measurements of contrast-enhancing tumor
regions, corticosteroid dosing, and clinical assessment to arrive
at a designation of response, stable disease, or progression.
Recent advances in imaging technology and targeted therapeu-
tics, however, have exposed limitations of the Macdonald
criteria and have highlighted the need for reevaluation of
response assessment criteria. In 2010, the Response Assess-
ment in Neuro-Oncology (RANO) Working Group published
updated criteria to address this need and to standardize re-
sponse assessment for high-grade gliomas. In 2009, prior to
the publication of the RANO criteria, the randomized, placebo-
controlled, multicenter, phase 3 AVAglio trial was designed
and initiated to investigate the effectiveness of radiotherapy
and temozolomide with or without bevacizumab in newly
diagnosed glioblastoma. The AVAglio protocol enacted
specific measures to adapt the Macdonald criteria to the front-
line treatment setting and to antiangiogenic agent evaluation,
including the incorporation of a T2/fluid-attenuated inversion
recovery component, qualitative assessment of irregularly
shaped contrast-enhancing lesions, and a decision tree for
confirming or ruling out pseudoprogression. Moreover, the
protocol outlines practical means by which these adapted
response criteria can be implemented in the clinic. This article
describes the evolution of radiographic response criteria for
high-grade gliomas and highlights the similarities and differ-
ences between those implemented in the AVAglio study and
those subsequently published by RANO.
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Introduction
Glioblastoma is the most common primary brain tumor in the
United States, with a reported incidence of approximately 3.
19 cases per 100,000 person-years (~9400 cases per year) [1].
Median overall survival (OS) for patients with newly diag-
nosed glioblastoma ranges from 12–18 months when treated
with the current standard of care [2, 3], and fewer than 10% of
patients survive beyond 5 years after diagnosis [4]. The
poor prognosis associated with glioblastoma underscores
the ongoing need for the development and characterization of
new therapeutic regimens.
Important measures of treatment efficacy in phase 2 and 3
trials of patients with glioblastoma include OS, radiographic
response, and duration of tumor control (ie, progression-free
survival [PFS]) [5, 6]. Although OS is considered the gold
standard clinical end point, it does not directly measure the
impact of a specific regimen because of the confounding effects
of salvage therapy and other variables. As a consequence, both
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radiographic response rate (RR) and PFS are valuable end
points when attempting to isolate the relative efficacy of a given
treatment and to understand the nature of on-study progression
[5, 7]. These surrogate measures of tumor burden, however,
have well-documented limitations, including the potential for
variability, the potential for false-positive signals, and the
discordance in radiograph interpretation between observers
[8]. As a result, methodologies and techniques that are used
to determine tumor response and progression continue to
evolve, with the goal of minimizing inherent errors and
enhancing accuracy. Neuro-oncologists have also included
additional measures (eg, neurologic examinations, use of ste-
roids) in response assessments to strengthen their value. The
continued refinement of response assessments is particularly
important in the context of an increasing number of agents that
are evaluated in patients with glioblastoma.
Historical Means of Response Assessment in Gliomas
and the Macdonald Criteria
Prior to 1990, the primary means of assessing response to
therapy in patients with glioblastoma were the Levin criteria
and World Health Organization (WHO) oncology response
criteria [9, 10]. The Levin criteria involve qualitative imag-
ing assessments that account for a number of factors, in-
cluding edema and mass effect [9]. The WHO response
criteria use contrast-enhanced computed tomography to
measure tumor area by multiplying the maximal cross-
sectional enhancing tumor diameters [10]. These criteria
were useful but limited in clinical practice by the subjective
variability of interpreting radiographs and poorly defined
response designations, and from subsequent observations
that contrast enhancement can be affected by factors
unrelated to the tumor [5].
The Macdonald criteria were subsequently proposed and
adopted to improve on previous assessment methodologies,
specifically by standardizing definitions of radiographic re-
sponse. Because contrast enhancement may be nonspecific
or indeterminate in nature, additional measures were includ-
ed to account for the impact of corticosteroid use and to
ensure that clinical assessments—specifically, neurologic
status—were considered when applying response designa-
tions. The Macdonald criteria classify responses into 4 cat-
egories; complete response (CR), partial response (PR),
stable disease (SD), and progressive disease (PD), borrow-
ing terminology familiar to solid-tumor oncology [11]
(Table 1). As the most frequently used means of response
assessment in glioblastoma, these more objective criteria
facilitated comparison of RR and PFS across clinical
trials [12••].
TheResponse Evaluation Criteria in Solid Tumors (RECIST)
guidelines for solid tumors (including gliomas), used
unidimensional measurements of target lesions but were
not specific for brain tumors and did not take the use of
steroids or clinical status into account [13, 14]. However,
comparisons of unidimensional (diameter), bidimensional
(area), and volumetric measurements of T1 gadolinium-
enhanced and T2-weighted MRI scans in a small series of
h igh-grade gl iomas tha t were no t t r ea ted wi th
antiangiogenic agents have generally shown good agree-
ment between the various methods of tumor assessments
[15, 16]. A retrospective analysis also demonstrated strong
concordance between different methods of assessment, in-
cluding RECIST guidelines and the Macdonald criteria,
when measuring response to and progression on irinotecan
and bevacizumab combination therapy in relapsed glioblas-
toma [17•].
Modern Challenges to Response Assessment
Over the ensuing 2 decades since the publication of the Mac-
donald criteria, improvements in imaging technology, the im-
pact of new therapeutic agents on underlying disease, and other
factors have prompted the need for corresponding advances in
response assessment of glioblastoma [12••, 18, 19]. Most ap-
parent has been the need to broaden the scope of the Macdon-
ald criteria to incorporate non-contrast-enhancing components
of tumor, account for the variability in contrast-enhancing
lesions, and define the timeframe of radiographic scans.
The evaluation of non–contrast-enhancing lesions using
T2-weighted or fluid-attenuated inversion recovery (FLAIR)
MRI sequences is critical for measuring infiltrative or diffuse
tumor growth. Pathologically, glioblastoma includes both in-
filtrative and vascularized components [20, 21]. Moreover,
diffuse radiographic patterns of disease are apparent in glio-
blastoma, even at diagnosis, although local patterns of disease
and recurrence predominate [20]. Finally, infiltrative tumor
growth, potentially occurring via cooption of preexisting
vasculature [22, 23], is a radiologic and histopathologic
finding after treatment with agents that inhibit vascular endo-
thelial growth factor (VEGF-A) [20, 24–26]. Consequently,
nonenhancing regions of the tumor, which are not included in
response designations per Macdonald criteria, should be con-
sidered to accurately assess the extent of biologically and
clinically relevant glioblastoma [27]. That said, variations in
T2-weighted or FLAIR images have proven difficult to
quantitatively assess, and no standardized threshold for
determination of PD has been established.
Another challenge with response criteria is related to
assessment variability of contrast-enhancing tumor. On the
basis of their mechanisms of action, agents that target VEGF-A
or its receptor (ie, bevacizumab, aflibercept, and cediranib)
affect vascular permeability [26, 28, 29], which, in turn, in-
fluences both the leakage of gadolinium into the brain and the
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Table 1 Response assessment criteria in the first-line treatment of glioblastoma
Macdonald AVAglio RANO RTOG 0825





• Disappearance of all
index lesions (sustained
for ≥4 weeks)
• Disappearance of all
enhancing measurable
and nonmeasurable disease
(sustained for ≥4 weeks)
• Disappearance of all
enhancing disease
(sustained for ≥1 mo.)
• No worsening of
all nonindex lesions
(sustained for ≥4 weeks),
with no evidence of PD







• No new lesions • Improved or stable
neurologic symptoms
• No corticosteroids • No new lesions • No new lesions








• Improved or stable
neurologic symptoms
• Clinically stable or
improved




• ≥50% decrease (sum
of lesion diameters)
of all index lesions
(sustained for
≥4 weeks)b








• No new lesions • No progression of
nonindex lesions
• No progression of
nonmeasurable disease
• Stable or reduced
corticosteroid dose
• Stable or reduced
corticosteroid dose
• No new lesions • Stable or improved
nonenhancing (T2/FLAIR)
lesionsc
• Improved or stable
neurologic symptoms
• Clinically stable or
improved
• Stable or reduced
corticosteroid dose
• No new lesions
• Improved or stable
neurologic symptoms




• Clinically stable or
improved
Minor responsea • Not applicable • Not applicable • Only applies to
low-grade gliomas
[51]
• <50% decrease in
diameter products
of enhancing disease
• Stable or reduced
corticosteroid dose
Stable diseasea • Clinically stable • Does not qualify for
CR, PR, or progression
• Does not qualify for
CR, PR, or progression
• Scan shows no change
• Does not qualify
for CR, PR, or
progression




• Stable or reduced
corticosteroid dose
• Corticosteroid dose
alone does not affect
determination of SD
• Stable or reduced
corticosteroid dose
• Clinically stable or
improved
Progressiond • ≥25% increase in
enhancing lesionsb
• ≥25% increase in
index lesionsb













(not caused by comorbid
events)
• Any new lesion
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extent of contrast enhancement on imaging. Furthermore,
many tumor-extrinsic factors also modulate vascular perme-
ability [30–34], and the effects of radiation (or chemoradiation)
are of particular relevance in the setting of newly diagnosed
glioblastoma. Increased contrast enhancement or edema that
occurs during or after treatment can mimic early tumor pro-
gression on MRI scans [35•, 36]. This increase, termed
pseudoprogression, has been observed in 10%–30% of all
patients with glioblastoma who are undergoing their first
post-therapy MRI examination following radiotherapy with
concurrent temozolomide [37, 38] and in 30%–48%of patients
who exhibit progression within 1 month of the end of radio-
therapy [39, 40]. The finding appears to be most common in
patients with tumors that have a methylated MGMT promoter
[37]. The observed increase in contrast enhancement often
subsides without modifying therapy, but it does complicate
the interpretation of results in clinical trials and in general
practice because pseudoprogression may prompt the discon-
tinuation of otherwise effective adjuvant therapy and/or the
improper assignment of a PFS event [5]. Clinical researchers
now frequently consider pseudoprogression when designing
clinical trials to ensure patients enrolled in trials in
recurrent settings are real progressors, but the effect of
pseudoprogression on response criteria and PFS in the front-
line setting has only recently begun to be addressed.
Finally, specifications on the timing of baseline and
follow-up radiographic scans are needed because of their
relationship to interpretation. Imaging at a number of time
points may be informative, including immediate post-
treatment and mid-radiotherapy scans, but it may not be
appropriate for making clinical decisions. Many studies
require a new baseline scan at study entry, and, although
of critical importance, such scans may be difficult to mea-
sure and interpret because of differences between the 2-to-
4–day postoperative and preradiotherapy scans, the variability
in the 2-to-6–week postoperative interval related to surgery
and normal healing, the prevalent use of corticosteroids, and
the variability of contrast associated with perioperative ische-
mia, which evolves over time [19, 27, 41]. Furthermore, very
early progression in the time between surgery and the start of
radiotherapy has been described, which may affect further
evaluation.
Ultimately, it is essential to have an appropriate baseline
assessment and a consistent approach to pseudoprogression
in newly diagnosed glioblastoma to accurately determine
the time of tumor progression with regard to time of clinical
trial enrollment and/or start of drug therapy.
Modified Response Criteria in Relapsed Glioblastoma
In recognition of the mechanism of antiangiogenic therapies
and the potential challenges with response assessment [39, 42,
43], pivotal studies of bevacizumab, a humanized monoclonal
antibody targeting VEGF-A, used modified criteria in the
setting of recurrent disease. The BRAIN study, initiated in
2006, was the first randomized, multicenter phase 2 trial to
evaluate the effectiveness and safety of bevacizumab with or
without irinotecan in patients with relapsed glioblastoma [44].
In BRAIN, response assessment of contrast-enhancing lesions
was based on WHO radiographic criteria, with an additional
requirement of stable or decreasing doses of corticosteroids
for determination of a response. A confirmatory MRI scan
was performed 4 or more weeks after an observed response.
Table 1 (continued)
Macdonald AVAglio RANO RTOG 0825
• Clinical deterioration • Any new lesion • Any new lesion • Worsened neurologic
symptoms (only applies




if corticosteroid dose is
stable or increased)
• Clear clinical deterioration
(not attributable to other
causes from the tumor or
changes in corticosteroid
dose)
• Clear progression of
nonmeasurable disease
CR complete response, PD progressive disease, PR partial response, SD stable disease.
a Response is designated only if all of the following criteria are met.
bMeasured by sum of the products of perpendicular diameters.
c On same or lower dose of corticosteroids.
d Progression is designated if any of the following criteria are met.
e On stable or increasing doses of corticosteroids.
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While non-contrast-enhancing lesions were considered non-
target lesions for tumor evaluation, any new area of
nonenhancing T2 or FLAIR signal consistent with tumor
was considered progressive disease. Furthermore, clinical
progression could be used as an indicator of progressive tumor
in the absence of radiographic documentation [44].
In a subsequent phase 2 trial of single-agent bevacizumab
in recurrent glioblastoma, MRI scans were evaluated
according to both modified Macdonald and Levin criteria
[45]. The study required that a scoring of SD or PR be
accompanied by stable or decreasing doses of corticoste-
roids, as well as by stable or improved areas of T2/FLAIR
abnormality. RRs of 35% and 71% were reported according
to the modified Macdonald and Levin criteria, respectively.
The authors suggested that the Levin criteria were a superior
method for assessing VEGF inhibition in situ because they
allow for early decreases in enhancement, edema, and mass
effect rather than for reductions in the diameter of the
enhancing tumor. Moreover, these early decreases assessed
with the Levin criteria were better correlated to PFS than
response evaluated with Macdonald criteria, although this
observation is limited given that it was the result of a small
single-center analysis [45].
Modified Response Criteria in Newly Diagnosed
Glioblastoma: The Phase 3 AVAglio Study
The initiation of several trials evaluating bevacizumab in
patients with newly diagnosed glioblastoma, specifically
the phase 3 AVAglio study, prompted further modifications
of assessment criteria in an attempt to improve accuracy
and reproducibility. In the AVAglio study (BO21990,
NCT00943826), one modification was to standardize all
aspects of radiological response assessment, including image
acquisition, timing of scheduled assessments, evaluation tech-
niques, and centralized review. TheAVAglio study, which began
enrollment in 2009, is a randomized, placebo-controlled, phase
3 trial investigating the effectiveness and safety of radiotherapy
and temozolomide with or without bevacizumab following sur-
gical resection or biopsy in newly diagnosed glioblastoma [46].
The coprimary end points of the study are OS and investigator-
assessed PFS; secondary end points are independent review
facility (IRF)-assessed PFS, 1- and 2-year survival rates, safety,
and health-related quality of life. Objective RR is being evalu-
ated as an exploratory end point.
The AVAglio protocol incorporated a number of adapta-
tions to the Macdonald criteria, including the expansion of
the radiographic element to encompass assessment of
nonenhancing tumor and more specific definitions of both
neurologic examinations and changes in corticosteroid use
that impact response assessment (Table 1). Neurologic exam-
ination and the mini-mental state examination (MMSE) are
used to assess the patient’s neurologic function relative to the
last disease assessment, with neurologic function reported as
improved, unchanged, or worsened. Similarly, corticosteroid
use is reported as increased, unchanged, or decreased at each
evaluation. All radiologic assessments are made using MRI,
and index (contrast-enhancing) and nonindex (both small
contrast—enhancing and nonenhancing) lesions selected at
baseline are assessed consistently at each subsequent time
point. Timing of radiologic assessments and treatment admin-
istration is shown in Fig. 1.
According to the radiographic aspects of imaging criteria
in the AVAglio protocol, index lesions are defined as all
measurable lesions (ie, contrast-enhancing lesions with clear
borders and having both diameters ≥10 mm) identified at
baseline. Investigators are instructed to select index lesions
Fig. 1 Overview of treatment and radiologic assessment schedule in
AVAglio. Disease assessment consists of radiologic assessment, neu-
rologic examination, including the mini-mental state examination, and
determination of corticosteroid use. Cy cycle, d days, HRQoL health-
related quality of life, PD progressive disease; w weeks
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based on their size (ie, lesions with the longest cross-
sectional diameters) and their suitability for accurate, re-
peat measurement. Radiologic assessments for index le-
sions are categorized as (1) CR, which is defined as the
disappearance of all index lesions that is sustained for
≥4 weeks; (2) PR, which is defined as a ≥50% decrease
of all index lesions (sum of the product of the greatest
diameters) that is sustained for ≥4 weeks; (3) SD, which
is defined as no sufficient decrease or increase of index
lesions to qualify as a PR or PD; and (4) PD, which is
defined as a ≥25% increase of all index lesions or any new
index lesion relative to baseline (Table 1).
Nonindex lesions include contrast-enhancing lesions that
are too small or irregular in shape to be considered measur-
able, as well as all nonenhancing lesions consistent with
tumor. In AVAglio, nonindex lesions are evaluated qualita-
tively for evidence of progression, and individual nonindex
lesions are recorded as being present, absent, or unable to
assess at each time point. Radiologic findings for nonindex
lesions are categorized as (1) CR, which is defined as the
disappearance of all nonindex lesions that are sustained for
≥4 weeks; (2) SD, which is defined as showing no signifi-
cant change in nonindex lesions; and (3) PD, which is
defined as any unequivocal increase of existing nonindex
lesions or any new nonindex lesion (Fig. 2).
A categorization of unable to assess is used for situations
in which both index and nonindex lesions cannot be reliably
measured for technical reasons (eg, radiograph is not com-
parable to baseline or is of poor quality), but not for situa-
tions of possible doubt of interpretation.
Patients who have undergone gross total resection and
have neither contrast-enhancing (index lesions) nor
nonenhancing lesions (nonindex lesions) on baseline MRI
are followed for recurrence. If no signs of progression are
observed, according to MRI, the radiologic assessment is
categorized as no change. The appearance of any index or
nonindex lesion consistent with tumor is categorized as PD.
To summarize, by incorporating a T2/FLAIR imaging
component and qualitative assessment of all nonindex le-
sions, the criteria set forth in AVAglio attempt to account for
changes in non–contrast-enhancing lesions and difficult-to-
measure residual disease.
Overall Implementation of Response Criteria in AVAglio
Importantly, the AVAglio protocol and imaging guidelines
serve to make the modified Macdonald criteria operational
in very specific terms. Information on neurologic status,
corticosteroid use, and radiologic assessment is interpreted
in an attempt to arrive at a dichotomous overall disease
Fig. 2 Illustration of a disease assessment of progressive disease based
on non–contrast-enhancing lesions in a 35 year old male with left
frontal glioblastoma. T1 contrast magnetic resonance imaging (MRI)
obtained immediately after completion of chemoradiation and
bevacizumab (a); 6 months later and continuing chemotherapy and
bevacizumab (b); and 12 months after completion of chemoradiation
and bevacizumab while continuing chemotherapy and bevacizumab
(c); show no evidence of contrast-enhancing tumor progression. T2
MRI obtained immediately after completion of chemoradiation and
bevacizumab (d); and 6 months later while continuing chemotherapy
and bevacizumab (e); show no tumor progression, but MRI obtained
12 months after completion of chemoradiation and bevacizumab while
continuing chemotherapy and bevacizumab (f); shows clear evidence
of T2 non–contrast-enhancing tumor progression with architectural
distortion of the left lateral ventricle (arrow)
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assessment of PD or non-PD, allowing the investigator to
readily assess atypical cases not normally covered under
standard response criteria (Table 2). As a result, patients
are not penalized with premature cessation of treatment
because of a too-strict application of response criteria.
All MRI scans used by the investigator for the radiologic
evaluation of overall tumor response in participating
patients are centrally reviewed by an IRF, facilitating an
unbiased analysis of PD. Thus, under strict and explicit
guidelines, both investigators and IRF reviewers are able
to follow the integrated response algorithm based on the
assessment of both index and nonindex lesions, with an
objective of reducing the variability observed thus far in
radiologic response designation (Table 3).
Assessment of Pseudoprogression in AVAglio
The AVAglio protocol also standardizes the assessment of
possible pseudoprogression. The potential occurrence of
pseudoprogression is evaluated at the first disease assess-
ment after radiotherapy (ie, 4 weeks after radiotherapy; see
Table 2). If the investigator observes a ≥25% increase in
index lesions and/or unequivocal progression of existing
nonindex lesions relative to the baseline disease assessment,
then the recommended assessment is pseudoprogression,
and treatment is continued under the provision that a con-
firmatory scan be performed 2 months later (ie, 12 weeks
after radiotherapy) (Fig. 3). If the confirmatory scan shows
further tumor progression as compared to the previous MRI,
the assessment is PD, and the patient is discontinued from
further treatment. In such cases, the date of the first disease
assessment after radiotherapy is considered to be the date of
PD. Conversely, if the confirmatory scan shows SD or PR as
compared to the previous MRI, the initial assessment is con-
firmed to be pseudoprogression, and the patient is continued
on treatment. In cases of confirmed pseudoprogression, the
measurements of first MRI after radiotherapy are used as the
new baseline (Fig. 4) but as a consequence, patients with
confirmed pseudoprogression are excluded from the response
analysis population.
Patterns of Progression
Additional to the assessment of response, an exploratory
end point in AVAglio is the assessment of patterns of
tumor progression. Progression patterns are categorized
Table 2 Definitions of progressive disease, pseudoprogression, and nonprogressive disease in AVAglio
Overall disease evaluation
Progressive disease • Progressive disease occurs when any of the following conditions are met:
- There was a ≥25% increase in the SPD of longest diameters of all index lesions compared with
the smallest recorded sum (nadir) during the study. In case of confirmed pseudoprogression, the
baseline scan is not taken into consideration as the nadir for further assessment
- Unequivocal progression of existing nonindex lesions
- Unequivocal appearance of ≥1 new lesions (index or nonindex)
- Neurologically worsened compared with neurologic evaluation at previous disease assessment,
and average daily corticosteroid dose must be unchanged or increased compared with the
previous disease assessment
• Progressive disease does not need a confirmatory scan
Pseudoprogression • Only applicable at the disease assessment performed prior to the start of the maintenance phase
1. There was a ≥25% increase in the sum of the longest perpendicular diameters of all enhancing
lesions compared with baseline. If pseudoprogression is observed on nonenhancing lesions, then
unequivocal progression of existing nonenhancing lesions
and
2. No appearance of new lesions outside of the radiation field
and
3. Patient should not have significant clinical neurologic worsening
• Concomitant decrease in steroid dose in the 2 months after radiation should rule out the designation
of progressive disease at this time point
• Pseudoprogression will be confirmed at the next disease assessment, performed 2 months later, and
will designate if the patient continues treatment or not
Nonprogressive disease • All other scenarios
• In patients with gross total resection with neither measurable nor nonmeasurable disease for which
there is no change in the radiologic assessment (no change)
SPD sum of the product of the diameters.
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as local (focus of enhancement or non-enhancing tumor
with mostly distinct or well-defined borders), multifocal
(>1 enhancing or nonenhancing tumor with intervening
areas of normal brain signal), or distant disease (a
single new focus of enhancement or nonenhancing tumor
centered outside a 30 mm margin around the primary site or
margin of the resection cavity). Once the tumor pattern was
determined (local, multifocal, distant), the diffuse (infiltrative)
pattern was reported as either present or not present. Scans are
categorized for tumor pattern at each disease assessment, and
an additional MRI is performed 9 weeks after the determina-
tion of PD for all patients to further assess this radiographic
end point.
The Response Assessment in Neuro-Oncology (RANO)
Working Group Criteria
After the initiation of the AVAglio study, the RANOWorking
Group published updated response criteria to implement a
consistent approach for future trials in high-grade glioma
[12••]. Because the RANO criteria were only recently pub-
lished, they have yet to be validated in a large clinical trial. It is
notable that the majority of the steps taken by the AVAglio
study to improve assessment methodology are also addressed
in the RANO criteria (Table 1). Both criteria consider (without
measuring) nonenhancing lesions via T2/FLAIR imaging in
assessing response, and both also contain specific guide-
lines to aid reviewers in distinguishing pseudoprogression
from true PD [12••].
There are, however, several nuances of the AVAglio
criteria and the proposed RANO criteria that warrant further
discussion. In the RANO guidelines, patients must be “sta-
ble or improved clinically” to qualify for a CR, PR, or SD
designation, but the RANO guidelines do not include a










CR CR/SD No CR
CR UA/ND No UA
PR CR/SD No PR
PR UA/SD No UA
SD CR/SD No SD
SD UA/ND No UA
UA SD No UA
PD Any Yes/No PD
Any PD Yes/No PD
Any Any Yes PD
NAa SD No SD
NAa NAb No No change
CR complete response, ND not detectable, PD progressive disease, PR
partial response, SD stable disease, UA unable to assess.
a NA = no index lesions identified at baseline.
b NA = no nonindex lesions identified at baseline.
Fig. 3 Decision-making flow chart in patients with signs of pseudoprogression in AVAglio. PD progressive disease
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precise recommendation on how clinical deterioration is to
be measured, although it is suggested that KPS, Eastern
Cooperative Oncology Group performance status, or WHO
performance score may be considered when making clinical
evaluations [12••]. By contrast, when AVAglio specifies that
patients exhibiting a response or SD must also have stable or
improved neurologic symptoms, specific instructions on
how neurologic status is to be evaluated are included in
the protocol; namely, by regularly scheduled neurologic
examinations and MMSEs, which take place concomitantly
with radiologic assessments.
Pseudoprogression is also handled differently in the guide-
lines proposed by RANO than in those by AVAglio. The
RANO criteria suggest that within the first 12 weeks after the
completion of radiotherapy, “progression can only be deter-
mined if the majority of new enhancement is outside of the
radiation field or if there is pathologic confirmation of progres-
sive disease” [12••]. In AVAglio, a prespecified follow-up scan
12 weeks after radiotherapy is required upon an initial obser-
vation of increased contrast-enhancement to confirm or rule
out pseudoprogression. Although this measure precludes
the conduct of restaging scans at an earlier time point, it
serves to standardize the review process by integrating
pseudoprogression into the response assessment algorithm.
Amore recent publication from the RANOWorking Group
has outlined a separate but related set of guidelines for re-
sponse assessment criteria in postoperative cases of newly
diagnosed glioblastoma [47]. These guidelines apply to sur-
gically delivered therapies (eg, brachytherapy, implanted che-
motherapy wafers), radiosurgery, and immunotherapy, which
are not specifically addressed in the AVAglio study protocol
since these treatments were not planned in AVAglio.
Conclusions
In the 20 years since its initial publication, the Macdonald
criteria have performed admirably and supported many cru-
cial advances in the treatment of patients with glioblastoma
and other high-grade gliomas. Most importantly, the criteria
helped to standardize the interpretation of data and allowed
for better cross-trial comparison of certain results [12••].
However, advances in imaging capabilities coupled with
newly available therapies, which affect contrast enhance-
ment, have been the driving forces behind the development
of updated criteria capable of improving response assess-
ments in modern clinical trials for glioblastoma.
The application of MRI and other imaging modalities has
facilitated the use of imaging end points, such as PFS, as
surrogates for OS in clinical trials [18, 48]. Current imaging
techniques allow for more accurate measurement of
contrast-enhancing lesions, while incorporating information
on nonenhancing lesions into overall response assessments.
Despite having strong concordance, criteria that integrate
FLAIR appear to reduce response rates and PFS relative to
criteria that only consider contrast enhancement in relapsed
disease [17•]. Given the relatively short survival time of
patients with glioblastoma, accurate response measurements
are needed to ensure the continuation of effective therapy
and, conversely, the timely termination (or modification) of
ineffective therapy in nonresponding patients [3, 27].
Optimally, the PFS end point should be reinforced by other
measures of therapeutic response to reflect an overall clinical
benefit. Performance status is one such measure, in which
benefit is evaluated on the basis of an improvement in or the
maintenance of the patient’s status. Although clear guidelines
have not been established, the duration of functional indepen-
dence (KPS >70) could be considered. Second, neurocognitive
status might appear as an important component in defining
overall clinical benefit. The AVAglio study used neurological
examination and MMSE as global assessments of
neurocognitive function. While the MMSE is a well-
validated screening tool for assessing dementia and cognitive
decline [49], use of more adaptive neurocognitive assessment
tools may provide additional sensitivity. However, such tools
may be difficult to implement in a large, multicenter random-
ized trial setting. Corticosteroid use can also serve as an
objective measure, but different criteria employ different
Fig. 4 Illustration of pseudoprogression in a 52-year-old patient with
left parietal malignant glioma. T1 contrast-enhancing magnetic reso-
nance imaging (MRI) shows a gross total resection (a). Four weeks
after completion of chemoradiation, MRI showed a new area of
contrast enhancement surrounding the collapsed surgical cavity (b).
Two months after initiation of maintenance temozolomide, MRI
showed diminution of the contrast enhancing area (c), which was
further diminished after an additional months (d)
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methodologies to evaluate corticosteroid dosing during re-
sponse assessment (ie, which interval to use for analyses and
what constitutes an increase or decrease in dosing). Lastly,
quality-of-life measures that consider patients and caregivers
may be taken into account to supplement or reinforce radio-
logic results [50].
The AVAglio study protocol proactively adapted the
existing Macdonald criteria to address specific limitations
and, subsequently, provided a more precise and operational
assessment of response and progression than permitted by the
previous criteria. These criteria were developed and initiated
prior to those proposed by the RANO Working Group. Al-
though the 2 sets of criteria are very similar with respect to
their major advances (ie, addressing pseudoprogression and
the integration of a T2/FLAIR component), the criteria set
forth in AVAglio include operational elements whose incor-
poration avoids some of the ambiguity found in the RANO
criteria and guidelines. This allows for more consistent and
rigorous application of the AVaglio criteria, which is especial-
ly important in a multicenter trial. Results of the AVAglio
study may serve to validate and critically assess the modifica-
tions to assessment contributed by study investigators.
A potential complication of the AVAglio algorithm related
to the observation of pseudoprogression is the issue of
rebaselining. Since the first MRI following treatment initiation
is used as the new baseline scan in cases of confirmed
pseudoprogression, it is necessary to exclude such patients
from response analyses. Indeed, the increase in the sum of the
product of the greatest tumor diameters associated with
pseudoprogression in the new baseline scan could lead to an
artificial assessment of PR during subsequent assessments.
Therefore, adaptations may be necessary to prevent a decline
in the population eligible for response analysis, particularly in
studies in which the sample size is smaller than in AVAglio.
Further evolution of both the AVAglio and RANO re-
sponse criteria is expected, and future refinements may
improve measurement techniques, allow for the ability to
assess nonenhancing lesions more objectively, or allow for
the categorization of delayed (continuing beyond 12 weeks
after radiotherapy) or late (starting beyond the 12-week time
window) pseudoprogression. Future modifications may also
include some measure of multimodal imaging (ie, perfusion,
diffusion, single-photon emission computed tomography, or
positron emission tomography) on a case-by-case basis
to aid investigators in determining response in certain
situations.
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